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Mechanisms and Management
of Diabetic Painful Distal Symmetrical
Polyneuropathy
SOLOMON TESFAYE, MD1
ANDREW J.M. BOULTON, MD2
ANTHONY H. DICKENSON, PHD3
Although a number of the diabetic neuropathies may result in painful symptomatology, this
review focuses on the most common: chronic sensorimotor distal symmetrical polyneuropathy
(DSPN). It is estimated that 15–20% of diabetic patients may have painful DSPN, but not all of
these will require therapy. In practice, the diagnosis of DSPN is a clinical one, whereas for
longitudinal studies and clinical trials, quantitative sensory testing and electrophysiological as-
sessment are usually necessary. A number of simple numeric rating scales are available to assess
the frequency and severity of neuropathic pain. Although the exact pathophysiological processes
that result in diabetic neuropathic pain remain enigmatic, both peripheral and central mecha-
nisms have been implicated, and extend from altered channel function in peripheral nerve
through enhanced spinal processing and changes in many higher centers. A number of pharma-
cological agents have proven efficacy in painful DSPN, but all are prone to side effects, and none
impact the underlying pathophysiological abnormalities because they are only symptomatic
therapy. The two first-line therapies approved by regulatory authorities for painful neuropathy
are duloxetine and pregabalin. a-Lipoic acid, an antioxidant and pathogenic therapy, has evi-
dence of efficacy but is not licensed in the U.S. and several European countries. All patients with
DSPN are at increased risk of foot ulceration and require foot care, education, and if possible,
regular podiatry assessment.
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T
he neuropathies are the most com-
mon long-term microvascular com-
plications of diabetes and affect those
with both type 1 and type 2 diabetes, with
up to 50% of older type 2 diabetic patients
having evidence of a distal neuropathy (1).
These neuropathies are characterized by a
progressive loss of nerve fibers affecting
both the autonomic and somatic divisions
of the nervous system. The clinical features
of the diabetic neuropathies vary im-
mensely, and only aminority are associated
with pain. The major portion of this review
will be dedicated to the most common
painful neuropathy, chronic sensorimotor
distal symmetrical polyneuropathy (DSPN).
This neuropathy has major detrimental ef-
fects on its sufferers, confirming an in-
creased risk of foot ulceration and Charcot
neuroarthropathy as well as being associ-
ated with increased mortality (1).
In addition to DSPN, other rarer
neuropathies may also be associated
with painful symptoms including acute
painful neuropathy that often follows peri-
ods of unstable glycemic control, mono-
neuropathies (e.g., cranial nerve palsies),
radiculopathies, and entrapment neuropa-
thies (e.g., carpal tunnel syndrome). By far
the most common presentation of diabetic
polyneuropathy (over 90%) is typical
DSPN or chronic DSPN.
TheTorontoDiabeticNeuropathyEx-
pert Group recently defined DSPN as “a
symmetrical, length-dependent sensori-
motor polyneuropathy attributable to
metabolic and microvessel alterations
as a result of chronic hyperglycemia expo-
sure and cardiovascular risk covariates” (2).
An abnormality of nerve conduction (NC)
tests, which is frequently subclinical, ap-
pears to be the first objective quantitative
indication of the condition. The occurrence
of diabetic retinopathy and nephropathy
in a given patient strengthen the case that
the polyneuropathy is attributable to diabe-
tes. DSPN results in insensitivity of the feet
that predisposes to foot ulceration (1) and/
or neuropathic pain (painful DSPN), which
can be disabling.
Clinical features of painful
DSPNdThe onset of DSPN is usually
gradual or insidious and is heralded by
sensory symptoms that start in the toes
and then progress proximally to involve
the feet and legs in a stocking distribution.
When the disease is well established in the
lower limbs in more severe cases, there is
upper limb involvement, with a similar
progression proximally starting in the
fingers. As the disease advances further,
motor manifestations, such as wasting of
the small muscles of the hands and limb
weakness, become apparent. In some
cases, there may be sensory loss that the
patient may not be aware of, and the first
presentation may be a foot ulcer. Approx-
imately 50% of patients with DSPN ex-
perience neuropathic symptoms in the
lower limbs including uncomfortable tin-
gling (dysesthesia), pain (burning; shoot-
ing or “electric-shock like”; lancinating or
“knife-like”; “crawling”, or aching etc., in
character), evoked pain (allodynia, hy-
peresthesia), or unusual sensations (such
as a feeling of swelling of the feet or severe
coldness of the legs when clearly the
lower limbs look and feel fine, odd sen-
sations on walking likened to “walking
on pebbles” or “walking on hot sand,”
etc.). There may be marked pain on
walking that may limit exercise and
lead to weight gain. Painful DSPN is
characteristically more severe at night
and often interferes with normal sleep
(3). It also has a major impact on the
ability to function normally (both men-
tal and physical functioning, e.g., ability
to maintain work, mood, and quality of
life [QoL]) (3,4).
In one study from the U.S., the
burden of painful DSPN was found to
be considerable, resulting in a persistent
discomfort despite polypharmacy and
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high resource use and led to limitations
in daily activities and poor satisfaction
with treatments (4). The unremitting na-
ture of the pain can be distressing, resulting
in mood disorders including depression
and anxiety (4). The natural history of pain-
ful DSPN has not been well studied, and
there is a need for large, population-based,
prospective studies looking at the natural
history and potentially modifiable risk
factors, if any. However, it is generally
believed that painful symptoms may per-
sist over the years (5), occasionally be-
coming less prominent as the sensory
loss worsens (6).
EpidemiologydThere have been
relatively few epidemiological studies
that have specifically examined the prev-
alence of painful DSPN, which range from
10–26% (7–9). In a recent study of a
large cohort of diabetic patients receiving
community-based health care in northwest
England (n 5 15,692), painful DSPN as-
sessed using neuropathy symptom and dis-
ability scores was found in 21% (7). In one
population-based study from Liverpool,
U.K., the prevalence of painful DSPN as-
sessed by a structured questionnaire and
examination was estimated at 16% (8).
Notably, it was found that 12.5% of these
patients had never reported their symp-
toms to their doctor and 39% had never
received treatment for their pain (8), in-
dicating that there may be considerable
underdiagnosis and undertreatment of
painful neuropathic symptoms compared
with other aspects of diabetes management
such as statin therapy and management of
hypertension.
Risk factors for DSPN per se have
been extensively studied, and it is clear
that apart from poor glycemic control,
cardiovascular risk factors play a prom-
inent role (10): risk factors for painful
DSPN are less well known. Preliminary
epidemiological studies suggest clinical
correlates for painful DSPN compared
with painless DSPN to include weight
(11), obesity (12), waist circumference
(13), peripheral arterial disease (11,13),
and triglycerides (12). However, one lim-
itation of these studies was that assess-
ment of both DSPN and painful DSPN
was carried out using screening methods
(Michigan Neuropathy Screening Instru-
ment) questionnaire (11,13) or the Douleur
Neuropatique en 4 questions (12) for neu-
ropathic pain, and the neurological ex-
amination of Michigan Neuropathy
Screening Instrument (11,13) or Neuro-
pen (12) for assessment of DSPN.
Diagnosing and assessing
the severity of DSPN
and painful DSPNdA broad spec-
trum of presentations may occur in pa-
tients with DSPN, ranging from one
extreme of the patient with very severe
painful symptoms but few signs, to the
other when patients may present with a
foot ulcer having lost all sensation with-
out ever having any painful or uncomfort-
able symptoms; when pressed, such
patients may admit to the feet feeling
somewhat “numb” or “dead.” Thus, it is
well recognized that the severity of symp-
toms may not relate to the severity of the
deficit on clinical examination (1).
Diagnosing and assessing severity
of DSPN
The American Diabetes Association Con-
sensus Statement (14) recommended that
the diagnosis of painful DSPN in clinical
practice be a clinical one, relying on the
patient’s description of pain and typical
features of peripheral neuropathy mani-
festing in reduction of sensory modalities
and absence/reduction of ankle/knee re-
flexes. Because DSPN is a diagnosis of
exclusion, a careful clinical history and a
peripheral neurological and vascular ex-
amination of the lower limbs are essential
to exclude other causes of neuropathic
pain and leg/foot pain such as peripheral
vascular disease, arthritis, malignancy, al-
cohol abuse, spinal canal stenosis, etc. NC
studies are rarely helpful in clinical prac-
tice but might help in excluding other
causes of pain such as entrapment syn-
dromes. Patients with asymmetrical
symptoms and/or signs (such as loss of
an ankle jerk in one leg only), rapid pro-
gression of symptoms, or predominance
of motor symptoms and signs should be
carefully assessed for other causes of the
findings.
For longitudinal studies and clinical
trials in which a more accurate quantifi-
cation of neuropathy is required, the
Toronto Diabetic Neuropathy Consensus
Panel suggested a reliable objective and
quantitative measure; that is, NC abnor-
mality as the minimal criteria for the
diagnosis of DSPN (2). When NC values
have not been assessed, the Consensus
Panel recommended that it is not possible
to provide a “confirmed” diagnosis of
DSPNdonly a “possible” or “probable”
diagnosis.
However, subjects with pure small-
fiber neuropathy may be diagnosed by
quantitative sensory testing (QST) to as-
sess the psychophysical thresholds for
cold and warm sensations, heat and cold
pain, and pain to pin prick; or by cuta-
neous vasomotor function to measure
skin blood flow as a marker of c-fiber
neurovascular dysfunction (15). How-
ever, the gold standard for assessing small
fiber function remains quantification of
intraepidermal nerve fibers from punch
skin biopsy immunostained by PGP9.5
(16). Indeed, QST has also been routinely
used in some clinics to diagnose general
neuropathy (e.g., the 10-g monofilament
is widely used in diabetic clinics to screen
for DSPN), and recently, the German Pain
Network has developedQST to character-
ize the somatosensory phenotype of pa-
tients with neuropathic pain (17), though
the Toronto Consensus Panel recognized
its limitation of essentially being subjec-
tive and the potential for bias by percep-
tual/cognitive factors. Recent advances in
small fiber neuropathy assessment in-
clude brain-evoked potentials with elec-
trical and laser stimulation (laser-evoked
potentials) (18), and contact heat–evoked
potentialda measure of cerebral responses
of A-delta fiber–mediated thermonocicep-
tive stimuli (19).
There are several instruments that
evaluate combinations of neuropathy
symptoms, signs, and neurophysiological
test abnormalities giving scores for sever-
ity of DSPN (20–24). However, clinical
examination is not always reproducible,
and recent studies emphasize the impor-
tance of the proficiency of the clinical neu-
rological assessment (24). For controlled
clinical trials of DSPN, the Toronto Con-
sensus Panel advocated the use of an NC
test as an early and reliable indicator of the
occurrence of this neuropathy (2). The
group also emphasized that to be reliable
the test must be carried out rigorously,
using appropriate reference values cor-
rected for applicable variables (2).
Assessing neuropathic pain severity
The frequency and severity of painful
symptoms can be assessed by a number
of simple numeric rating scales (25). The
use of simple scales such as the visual an-
alog scale or the numerical rating scale,
such as an 11-point Likert scale (0 5 no
pain to 10 5 worst pain imaginable) is
recommended. These scales can then be
used to monitor response to treatment in
clinical practice or research context.
Other validated scales and questionnaires
include 1) the modified Brief Pain Inven-
tory Short Form (BPI-MSF) (26) recently
used as the primary end point in pharma-
cological treatment trials of painful
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DSPN; 2) the neuropathic pain symptom
inventory (27), which evaluates the differ-
ent symptoms and dimensions of neuro-
pathic pain; 3) the neuropathic pain
questionnaire (28), which consists of 12
items, including 10 related to sensations
and or sensory responses and 2 related to
affect; 4) the LANNS pain scale (29),
which contains five symptom and two clin-
ical examination items and is easy to score
within clinical settings; 5) painDETECT, a
screening tool that incorporates an easy to
use, patient based (self-report) question-
naire with nine items that do not require a
clinical exam (30); and 6) the McGill Pain
Questionnaire, whichmeasures the sensory
and affective components of pain, often
used in its shortened format (31).
QoL might be assessed by generic in-
struments thatmay allow cross comparison
with other chronic medical conditions.
However, it is also important to use vali-
dated, neuropathy-specific measures of
QoL, such as the NeuroQol (32), that re-
liably capture the key dimensions of pa-
tients’ experience of DSPN and is a valid
tool for studying the impact of neuropathy
and foot ulceration on QoL. Another
neuropathy-specific measure of QoL is
the Norfolk Quality of Life Scale (33),
which is a validated patient-reported out-
comemeasure, sensitive to the different fea-
tures of diabetic neuropathy including
small-fiber, large-fiber, and autonomic
function. There are a number of scales
that might assess pain behavior and sleep
interference and the prediction of re-
sponse to therapy (34). Finally, the impact
of painful symptoms on mood can be as-
sessed using the Hospital Anxiety and
Depression Scale (35) and Beck’s Depres-
sion Inventory (36).
Mechanism of neuropathic
pain in diabetesdWe will now
consider the changes at central and pe-
ripheral levels induced by DSPN that
relate to the sensory changes experienced
by patients and the mechanisms that
treatments are thought to modulate.
The exact pathophysiological mecha-
nisms of neuropathic pain in diabetes
remain elusive although several mecha-
nisms have been postulated (Table 1)
(37). Other potential mechanisms in-
clude the association of increased blood
glucose instability in the genesis of neu-
ropathic pain (38), an increase in periph-
eral nerve epineurial blood flow (39),
altered foot skin microcirculation (40),
reduced intraepidermal nerve fiber den-
sity in the context of early neuropathy
(41), increased thalamic vascularity (42),
and autonomic dysfunction (43).
The fact that diabetes induces neu-
ropathy and that in a proportion of
patients this is accompanied by pain de-
spite the loss of input and numbness,
suggests that marked changes occur in the
processes of pain signaling in the periph-
eral and central nervous system. Neuro-
pathic pain is characterized by ongoing
pain together with exaggerated responses
to painful and nonpainful stimuli, hyper-
algesia, and allodynia. These combina-
tions of loss and gain of function have
been recently characterized by sensory
testing by Maier et al. (44), and five sub-
groups of patients emerge with many of
the signs and symptoms overlapping with
those seen in patients with postherpetic
neuralgia. This suggests common mecha-
nisms but importantly, the subgroups
may turn out to have different responses
to pharmacological agents and so lead to a
prediction of analgesic response. Never-
theless, the changes seen suggest altered
peripheral signaling and central compen-
satory changes perhaps driven by the loss
of input. Indeed, the descriptors used,
such as electric shock, burning, and lan-
cinating indicate that diabetes induces
changes in the way peripheral signals are
processed.
Capsaicin in chili peppers evokes
burning pain due to activation of transient
receptor potential channel (TRP) V1, a
receptor situated on small peripheral
fibers and part of the family of 27 TRP
channels cloned in humans (45), some of
which are thought to transduce thermal
signals (46) and include TRPM8 and
TRPA1, important in cold hypersensitiv-
ity (47). Local application of capsaicin can
be analgesic in localized painful neurop-
athies, and polymorphisms in TRPV1 can
explain some of the variation in pain seen
after neuropathy in patients (48).
There are many other less understood
or characterized peripheral sensors, in-
cluding the P23 receptors for ATP, re-
leased from all damaged cells suggesting
further potential targets for therapies
(49). Very clear evidence points to the
key role of changes in ion channels as a
consequence of nerve damage and their
roles in the disordered activity and trans-
duction in damaged and intact fibers (50).
Sodium channels depolarize neurons
and generate an action potential. Follow-
ing damage to peripheral nerves, the
normal distribution of these channels
along a nerve is disrupted by the neuroma
and “ectopic” activity results from the ac-
cumulation of sodium channels at or
around the site of injury. Other changes
in the distribution and levels of these
channels are seen and impact upon the
pattern of neuronal excitability in the
nerve. Inherited pain disorders arise
from mutated sodium channels, notably
gain and loss of functions of the sodium
channel Nav 1.7 (51,52), and polymor-
phisms in this channel impact on the level
of pain in patients, indicating that inherited
differences in channel function might
explain some of the variability in pain be-
tween patients with DSPN (53). Following
peripheral nerve damage, levels of another
sodium channel, Nav 1.3, in dorsal root
ganglia increase and are thought to sup-
port ectopic neuronal firing. Blockers of
these pain-related channels and also the
very important Nav1.8 have been pro-
duced but have yet to reach the clinic.
Thus, treatments revolve around nonse-
lective sodium channel blockers including
local anesthetics such as lidocaine and the
anticonvulsant carbamazepine in trigemi-
nal neuralgia (54).
A recent study (55) proposes a mech-
anism for the observed neuropathic
changes that follow diabetes. The levels
of the glycolytic metabolite methyl-
glyoxal distinguished between diabetic
patients with pain and those without
pain. Methylglyoxal activated peripheral
nerves and altered the function of Nav 1.8,
and Nav 1.7. In animals, the metabolite was
found to slow NC, increase release of calci-
tonin gene-related peptide from nerves, and
cause thermal and mechanical hyperalgesia.
Table 1dMechanisms of neuropathic pain
Peripheral mechanisms
Changes in sodium channel distribution
and expression




Loss of spinal inhibitory control
Altered peripheral blood flow
Axonal atrophy, degeneration, or
regeneration




Changes in the balance of facilitation/
inhibition within descending pathways
Increased thalamic vascularity
Adapted with permission from Tesfaye and
Kempler (37).
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This hyperalgesia was reflected by func-
tional changes in pain-related areas of
the brain (55).
Where sodium channels act to gener-
ate action potentials, potassium channels
serve as the molecular brakes of excitable
cells, playing an important role in mod-
ulating neuronal hyperexcitability. The
drug retigabine, a potassiumchannel opener
acting on the channel (KV7, M-current)
opener, blunts behavioral hypersensitivity
in neuropathic rats (56) and also inhibits C
and Ad-mediated responses in dorsal horn
neurons in both naïve and neuropathic rats
(57), but has yet to reach the clinic as an
analgesic although it has recently been ap-
proved by the FDA as an add-on treatment
of partial seizures (58).
There are likely many other changes
in potassium channels after neuropathy,
and their importance is underscored by
the fact that opioids act to open these
channels and suppress activity in pain
pathways by actions at both spinal and
brain sites.
The third channel set in neuronal
events is made up of voltage-gated Ca
channels, which serve to release transmitter.
In the case of afferent sensory fibers, these
are glutamate and peptides such as sub-
stance P. Following nerve injury, a2d sub-
units of these channels are slowly
upregulated in the central terminals of pe-
ripheral nerves, so favoring increased re-
lease of these transmitters into the spinal
cord (59). This will therefore compensate
for the loss of afferent fibers produced by
the neuropathy. Gabapentin and pregabalin
target the a2d subunit and by preventing its
trafficking into the membrane reduce the
abnormal transmitter release (59).
A further permissive factor in the
actions of these drugs is activity in spinal
5-hydroxytryptamine 3 receptors, them-
selves driven by activity in descending
pathways from the brain; this rapidly
switching circuit may not only explain
the actions of a2d ligands after nerve in-
jury but also their acute effects such as
those seen after surgery (60).
Central excitatory mechanisms
Ad and C fibers terminate primarily in the
superficial laminae of the dorsal horn
where the large majority of neurons are
nociceptive specific (Fig. 1). Some of
these neurons gain low threshold inputs
after neuropathy and these cells project
predominantly to limbic brain areas such
as the periaqueductal gray, lateral parabra-
chial nucleus, thalamus, nucleus tractus
solitarius, and the medullary reticular for-
mation. Within deeper lamina V, neurons
are wide-dynamic range, responding to
both innocuous and noxious stimuli, and
so candidates for abnormal coding of low-
threshold inputs and hence allodynia, ex-
hibiting wind-up and projecting to sensory
areas of the brain such as the thalamus and
thence the cortex, where the sensory com-
ponent of pain is represented (Fig. 2).
Thus, spinal cord neurons provide paral-
lel outputs to the affective and sensory
areas of the brain. Changes induced in
these neurons by repeated noxious in-
puts underpin central sensitization where
the resultant hyperexcitability of neurons
leads to greater responses to all subse-
quent inputsdinnocuous and noxiousd
expanded receptive fields and enhanced
outputs to higher levels of the brain (Fig.
2). These changes may then alter descend-
ing controls (Fig. 2). The spinal mecha-
nisms involve the actions of glutamate
Figure 1dA representation of the central spinal and peripheral changes that accompany neuropathy. The existence of a lesion or disease
of a peripheral sensory nerve alters the conduction and transmission of sensory messages. The normal transfer of modalities (top right) onto
spinal nociceptive specific (NS) and wide-dynamic range (WDR) neurons is changed by ectopic activity, sensory loss, and changes in ion
channels. Spinal cord neurons are subject to many receptor-mediated events, but increases in Ca channel function lead to increased transmitter
release so that glutamate causes an enhanced activation of AMPA and NMDA receptors. Substance P acts on neurokinin 1 (NK1) receptors to
add to the excitation. Reduced spinal inhibition through g-aminobutyric acid (GABA) and the transporter potassium-chloride transporter
member 5 (KCC2) aids enhanced pain messages. Reduced noradrenaline (NA) descending inhibition via a-2 adrenoceptors and increased
5-hydroxytryptamine (5HT) descending excitation via 5HT3 receptors add to the dominance of excitatory transmission. m-Opioid receptors
(MOR) are found on this circuitry.
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and its coreleased transmitter substance
P permitting N-methyl-D-aspartate (NMDA)
receptor activation, resulting in the wind-
up of dorsal horn neurons. The analgesic
effects of ketamine result from its ability
to modulate this activity through blocks
of the NMDA receptor (Fig. 1). However,
similarmechanistic events underliememory,
cognitive, and related functions and so the
side effects of ketamine result from a lack
of selectivity for spinal-pain related
NMDA functions (61).
As a consequence of these changes in
the sending of nociceptive information
within the peripheral nerve and then the
spinal cord, the information sent to the
brain becomes amplified so that pain
ratings become higher. Alongside this,
the persistent input into the limbic brain
areas such as the amygdala are likely to be
causal in the comorbidities that patients
often report due to ongoing painful inputs
disrupting normal function and generat-
ing fear, depression, and sleep problems
Figure 2dAn overview of the ascending (left) and descending (right) pain pathways. From the spinal cord there are spinoreticular projections and
dorsal column pathways to the cuneate nucleus (CN) and nucleus gracilis (NG). Other limbic projections relay in the parabrachial nucleus (PB) and
then project to the hypothalamus (Hyp) and amygdala (Am), where central autonomic function and fear/anxiety are processed. Spinothalamic
pathways run to the ventrobasal medial (VPM) and lateral (VPL) areas and then run to the somatosensory part of the cerebral cortex (CC) where the
location and the sensory components of pain are generated. Limbic brain areas (Am and Hyp) project down to the periqueductal gray (PAG) and to
the locus coereleus (LC), A5 and A7 nuclei, and the rostroventral medial medulla (RVM). Thence, descending noradrenaline (NA) inhibition viaa-2
adrenoceptors and increased 5-hydroxytryptamine (5HT) descending excitation via 5HT3 receptors modulates spinal cord activity. The changes
induced by peripheral neuropathy on these brain functions are depicted together with comorbidities, and genotypic and phenotypic factors are
shown.
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(Fig. 2). Of course, many patients report
that their pains are worse at night, which
may be due to nocturnal changes in these
central pain processing areas. Finally, the
neuropathic pain alters function and ac-
tivity in the descending controls, which
relay information from higher brain cen-
ters via the midbrain and brainstem to the
spinal cord. In healthy volunteers and
patients, a loss of inhibition or gain of
facilitation promotes pain whereas evok-
ing inhibition reduces pain (60). Preclin-
ical studies suggest that the bases for this
are descending noradrenergic, mostly in-
hibitory, and certain serotonergic con-
trols that facilitate pain (Figs. 1 and 2).
These monoamine descending controls
regulate spinal neuronal activity bidi-
rectionally and underlie the efficacy of
antidepressants for the treatment of
pain (60).
The increased analgesic effect of ta-
pentadol, recently shown to be effective in
animals and patients with diabetic neu-
ropathy, likely resides in synergistic in-
teractions between its weak opioid
actions at spinal and supraspinal sites
coupling to enhancing noradrenergic
controls and so reducing opioid load
(62). Interestingly, changes in the balance
of control from the braindthe gain in
descending facilitation coupled with a
loss of inhibitiondoccur in the later
stages after peripheral injury suggestive
of a role in maintaining but not initiating
the pain state. Furthermore, animal stud-
ies suggest that the recruitment of de-
scending inhibitions may be protective
and so can override the pain initiated by
the neuropathic damage to the peripheral
nerve (63).
So, overall, the mechanisms of pain in
diabetic neuropathy extend from altered
channel function in peripheral nerves
through enhanced spinal processing and
finally to changes in many higher centers
(Fig. 2).
Management of painful
DSPNdThe assessment and treatment
of painful DSPN should ideally involve a
multidisciplinary team that may include
a diabetologist, a neurologist, the pain
clinic team, specialist nurses, podiatrists,
psychologists, physiotherapists, occupa-
tional therapists, and others. However, in
most clinical settings this is not possible,
and the management falls mainly to the
diabetes physician, the primary care phy-
sician, or the neurologist. When treat-
ment is started, a realistic objective would
be to achieve around 50% reduction in
pain intensity. However, being “realistic”
shouldn’t be interpreted as less aggressive
pursuit of maximum pain relief. Second-
ary objectives should include restoration
or improvement in functional measures,
QoL, sleep, and mood. Although it is ho-
ped that improvement in pain will be fol-
lowed by improvement in functionality,
this may not be the case as many of these
patients may have other comorbidities.
Moreover, the multidisciplinary team
should discuss potential interventions in
addition to pharmacotherapy to help pa-
tients optimize function in the presence of
residual pain.
Although strong evidence implicates
poor glycemic control as a pathogenetic
mechanism in the etiology of DSPN, there
is no proof from randomized, controlled
trials that this is the case for neuropathic
pain in diabetes. However, as increased
blood glucose flux has been reported to
contribute to pain in DSPN (38), there is a
general consensus that good blood glu-
cose control should be the first step in
the management of any form of diabetic
neuropathy. Additionally, as cardiovas-
cular disease is common in patients
with DSPN (10) and vascular risk factors
(hypertriglyceridemia, hypertension, vis-
ceral obesity etc.) appear to be implicated
in the pathogenesis of DSPN (10,64),
there is a good rationale for management
of vascular risk factors beyond glycemic
control.
Pharmacological treatment
Several pharmacological treatments have
proven efficacy in the management of
painful DSPN, although only duloxetine
and pregabalin are approved for the treat-
ment of neuropathic pain in diabetes by
both the Food and Drugs Administration
of the U.S. and the European Medicines
Agency.
Pharmacological treatment of pain-
ful DSPN is not entirely satisfactory be-
cause currently available drugs are often
ineffective and complicated by adverse
events. Tricyclic compounds (TCAs)
have been used as first-line agents for
many years, but their use is limited by
frequent side effects that may be central
or anticholinergic, including dry mouth,
constipation, sweating, blurred vision,
sedation, and orthostatic hypotension
(with the risk of falls particularly in
elderly patients). For this reason, low-
dose amitriptyline or imipramine 10 mg
taken at night may be started. Depend-
ing upon efficacy and side effects, the
dose can gradually be increased to
75 mg/day and on occasions even up to
150 mg/day (1). Higher doses have been
associated with an increased risk of sud-
den cardiac death, and caution should
be taken in any patient with a history
of cardiovascular disease (65).
The selective serotonin noradrenalin
reuptake inhibitors (SNRI) duloxetine
and venlafaxine have been used for the
management of painful DSPN (65).
SNRIs relieve pain by increasing synap-
tic availability of 5-hydroxytryptamine
and noradrenalin in the descending
pathways that inhibit pain impulses.
The efficacy of duloxetine in painful
DSPN has been investigated in three
identical trials, and pooled data from
these shows that the 60 mg/day and
120 mg/day doses are effective in reliev-
ing painful symptoms, starting within 1
week and lasting the full treatment pe-
riod of 12 weeks (66). The main side
effects include nausea, somnolence, diz-
ziness, constipation, dry mouth, and re-
duced appetite, although these tend to
be mild to moderate and are transient.
It is advisable to start at 30 mg/day taken
with food for the first week and then
increase to the standard dose of 60
mg/day. Venlafaxine (150–225 mg/day)
is also effective in relieving painful
DSPN, although cardiovascular adverse
events limit its use in diabetes (67).
The anticonvulsant gabapentin, which
binds to the a2d subunit of the calcium
channel thereby reducing neurotransmitter
release in the hyperexcited neuron, gradu-
ally titrated from 100 mg t.i.d. to 3,600
mg/day is also effective (68). More recently,
there have been several clinical trials in-
volving pregabalin in painful DSPN, and
these showed clear efficacy in management
of painful DSPN (69). Unlike gabapentin,
pregabalin has linear pharmacokinetics,
doesn’t require a long titration period, and
is started at 75 mg b.i.d. for about a week
and increased to 150mg b.i.d.maintenance
dose with a maximum dose of 600 mg/day
(55). The side effects include dizziness,
somnolence, peripheral edema, headache,
and weight gain.
Other effective but generally consid-
ered second line drugs (65) for painful
DSPN include other anticonvulsants,in
particular carbamazepine (65), although
it has troublesome side effects including
dizziness, somnolence and gait distur-
bance; tramadol, a weak opioid and
weak inhibitor of noradrenaline and sero-
tonin reuptake (65); the strong opioid oxy-
codone controlled release (65); and topical
treatments including the substance-P
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depleter, topical capsaicin and the lido-
caine patch (65). Refractory cases of pa-
tients with painful DSPN may be treated
with intravenous lignocaine (5 mg/kg
over 30 min) (65). Of the pathogeneti-
cally oriented treatments for painful
DSPN only the antioxidant, a-lipoic acid
administered intravenously over 3 weeks




The European Federation of Neurologi-
cal Societies proposed that first-line treat-
ments might comprise of TCAs, SNRIs,
gabapentin, or pregabalin (71). The U.K.
National Institute for Health and Care
Excellence guidelines on the manage-
ment of neuropathic pain in nonspecialist
settings proposed that duloxetine should
be the first-line treatment with amitripty-
line as an alternative, and pregabalin as a
second-line treatment for painful DSPN
(72). However, this recommendation of
duloxetine as the first-line therapy was
not based on efficacy but rather cost-
effectiveness. More recently, the American
Academy of Neurology recommended
that pregabalin is “established as effective
and should be offered for relief of [painful
DSPN] (Level A evidence)” (73), whereas
venlafaxine, duloxetine, amitriptyline, ga-
bapentin, valproate, opioids, and capsai-
cin were considered to be “probably
effective and should be considered for
treatment of painful DSPN (Level B evi-
dence)” (63). However, this recommenda-
tion was primarily based on achievement
of greater than 80% completion rate of
clinical trials, which in turn may be influ-
enced by the length of the trials. Finally,
the International Consensus Panel on Di-
abetic Neuropathy recommended TCAs,
duloxetine, pregabalin, and gabapentin
as first-line agents having carefully re-
viewed all the available literature regard-
ing the pharmacological treatment of
painful DSPN (65), the final drug choice
tailored to the particular patient based on
demographic profile and comorbidities.
Tailoring treatment to individual
requirements
The initial selection of a particular first-
line treatment will be influenced by the
assessment of contraindications, evalua-
tion of comorbidities (including sleep
disturbance, mood disorders, and other
chronic medical/diabetes complications),
and cost (65). For example, in diabetic
patients with a history of heart disease,
elderly patients on other concomitant
medications such diuretics and antihy-
pertensives, and patients with comorbid
orthostatic hypotension TCAs have rela-
tive contraindications. In patients with
liver disease, duloxetine should not be
prescribed, and in those with peripheral
edema, pregabalin or gabapentin should
be avoided. Moreover, although pharma-
ceutical companies may recommend a
particular starting dose for their drugs
based on their clinical trials, one has to
appreciate that the clinical practice sce-
nario is different from clinical trial sce-
nario because many elderly patients
with multiple comorbidities would have
been excluded from trials. Therefore,
treatment has to be individualized to
take patient comorbidities including oc-
cupation, renal impairment, etc. into ac-
count, and caution is advised to start at
lower than recommended doses and ti-
trate gradually.
Comparator and combination trials
A major deficiency in the area of the
treatment of neuropathic pain in diabetes
is the relative lack of comparative or
combination studies. Virtually all previous
trials have been of active agents against
placebo, whereas there is a need for more
studies that compare a given drug with an
active comparator and indeed lower-dose
combination treatments (64). These issues
have been highlighted by recent consen-
sus guidelines from international institu-
tions that have emphasized the need for
large comparative and combination treat-
ment trials in painful DSPN as a matter of
priority (74,75).
Comparator trials. Bansal et al. (76)
compared amitriptyline with pregabalin
in painful DSPN in a small, randomized,
double-blind, crossover trial. This study
confirmed that whereas there was little
difference in efficacy, pregabalin was the
preferred drug because of a superior ad-
verse event profile. However, a major
drawback of this study was its small
size, involving 51 patients only with
many patients failing to complete the
study.
Another recent small crossover
study from the same group as the above
study has compared duloxetine with
amitriptyline (77). The study found
that both drugs were equally efficacious
although of the reported adverse events,
dry mouth was more common with am-
itriptyline than duloxetine (55 vs. 24%;
P , 0.01). Numerically, more patients
preferred duloxetine although this was
not statistically significant (48 vs. 36%;
P 5 0.18).
The lack of direct comparator studies
led to an indirect comparison of the
efficacy and tolerability of duloxetine
with that of pregabalin and gabapentin
in participants with painful DSPN, using
placebo as a common comparator (78).
Efficacy criteria were reduction in 24-h
pain severity for all three treatments, and
treatment response rate ($50% pain re-
duction), and overall health improve-
ment (as measured on the Patient
Global Impression of Improvement/
Change questionnaire) for duloxetine
and pregabalin only. Indirect compari-
son between duloxetine and gabapentin
found no statistically significant differ-
ences. Comparing duloxetine with pre-
gabalin, the authors found significant
differences in overall health improve-
ment, favoring pregabalin, and in dizzi-
ness, favoring duloxetine. There was
no significant difference in 24-h pain se-
verity between duloxetine and pregaba-
lin (78).
Combination trials. Gilron et al. (79)
studied nortriptyline and gabapentin ei-
ther in combination or alone in a ran-
domized trial and confirmed that when
given together, they were more effica-
cious than either drug given alone. In
another crossover study by the same
group, low-dose combination therapy
with gabapentin and morphine was sig-
nificantly more effective than higher
doses of either (80).
COMBO-DN study. The COMBO-DN
study that has just been completed (81)
is the largest combination trial in painful
DSPN and assessed whether combining
standard doses of duloxetine and prega-
balin is superior to increasing each drug
to its maximum recommended dose in
patients with incomplete pain relief. Pa-
tients with painful DSPN with a daily
pain score of at least 4 (scale 0–10)
were randomly assigned in a 1:1:1:1 ra-
tio to one of four groups. For the 8-week
initial treatment period, patients in
groups 1 and 2 were treated with 60
mg duloxetine/day; patients in groups
3 and 4 received 300 mg pregabalin/
day. Thereafter, only nonresponders
(,30% improvement in pain relief) re-
ceived double-blind treatment for fur-
ther 8 weeks of the combination versus
high-dose monotherapy treatment pe-
riod with duloxetine 120 mg/day for
group 1, duloxetine 60 mg/day1 prega-
balin 300mg/day for groups 2 and 3, and
pregabalin 600 mg/day for group 4. The
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primary outcome was change in the 24-h
average pain (an item from BPI-MSF) after
combination versus high-dose monother-
apy period (groups 1, 4 pooled versus
groups 2, 3 pooled).
Eight-hundred and four patients
were evaluated in the initial period and
339 in the combination versus high-dose
monotherapy treatment period, respec-
tively. The difference between combina-
tion and monotherapy in the mean
change of BPI-MSF average pain during
combination versus high-dose mono-
therapy treatment period was not statis-
tically significant (combination, 22.35;
monotherapy,22.16; P5 0.37) (81). Pro-
portions of patients with treatment emer-
gent adverse events were however similar:
36.7% (Combination) and 33.5% (Mono-
therapy). As a secondary end point the
COMBO-DN study also compared the ef-
ficacy of standard doses of duloxetine
and pregabalin as initial treatment for
painful DSPN, and duloxetine was
found to have superior efficacy com-
pared with pregabalin, without any
safety findings of concern. At the end of
the combination versus high-dose mono-
therapy treatment period, although the
groups are no longer randomized, 50%
pain relief was found in 46.9% of sub-
jects on 600 mg/day pregabalin com-
pared with 28.4% on 120 mg/day of
duloxetine.
Taken together, even though the pri-
mary end point was not met, the COMBO-
DN study demonstrated that at standard
doses duloxetine has better efficacy than
pregabalin as an initial treatment for painful
DSPN, without any safety findings of con-
cern. However, pregabalin catches up with
duloxetine in terms of efficacy as the doses
are increased to maximum.
ConclusiondA simple algorithm was
suggested by the Toronto International
Neuropathy Consensus meeting (Fig. 3)
to help practitioners in the management
of patients with painful DSPN (2,65). Af-
ter exclusion of other causes and optimi-
zation of glycemic control, first-line
therapies would include either an antide-
pressant (a tricyclic or duloxetine) or an
anticonvulsant (gabapentin or pregabalin).
These therapies all have level A evidence for
efficacy and a clear pathway of progression
if initial therapies fail is provided. Those
patients with the severest neuropathic
pain unresponsiveness to antidepressant
or anticonvulsant therapy might require
short-term treatment with opioid or
opioid-like drugs such as tramadol or
controlled release oxycodone. Finally,
it must always be emphasized that all
patients with any form of diabetic neurop-
athy are at increased risk of foot ulceration
and require education in self foot care and,
if possible, regular podiatry assessment and
treatment.
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